The FDA has approved infliximab-abda, a biosimilar for treating multiple rheumatic diseases, as well as abaloparatide for treating postmenopausal women with osteoporosis…

The FDA has approved infliximab-abda, a biosimilar for treating multiple rheumatic diseases, as well as abaloparatide for treating postmenopausal women with osteoporosis…
In a recent study, researchers examined the osteoclastogenic role of the histamine 4 receptor (H4R), measuring the peripheral blood and synovial fluid monocytes in patients with RA. Results showed that multiple cytokines stimulated H4R expression, suggesting the blockage of H4R may be a useful drug target to decrease the joint damage associated with RA…
On May 11, ACR leaders representing the Board of Directors, Affiliate Society Council, Government Affairs Committee (GAC), Committee on Rheumatologic Care, RheumPAC Committee and Insurance Subcommittee went to Capitol Hill to advocate on behalf of the ACR/ARHP membership and our patients. The group, which represents 27 states and the District of Columbia, conducted meetings in…
Angus Worthing, MD, FACP, FACR |
Greetings from your advocacy team in Washington, D.C.! The tectonic plates of the U.S. political landscape continue to shift. The latest: President Trump fired FBI Director James Comey on Tuesday, May 16; since then, Congress and journalists have had very little bandwidth for much else. But healthcare advocates remember just several news cycles ago when…
In an age of new medications for eye disease, rheumatologists and ophthalmologists must work together and communicate, says James Rosenbaum, MD. Teamwork and understanding how each specialty approaches the physical exam will aid patient care…
Philip L. Cohen, MD |
I read with pleasure the March 2017 Rheuminations (written by Simon M. Helfgott, MD), but wanted to make a small emendation. There is one other rheumatologist–Nobel Laureate besides Philip Hench. Baruch (Barry) Blumberg (1925–2011) was a bona fide rheumatologist who trained in the mid-1950s with the renowned Charles Ragan at Columbia-Presbyterian Medical Center in New…
Katarzyna Gilek-Seibert, MD, with Anais Ovalle, MD, Elias Jabbour, MD, Heather Ferri, DO, & Gabrielle Thottam, MD |
One day not too long ago, right smack in the middle of Thanksgiving and Christmas, I was sitting at the roundtable of our conference room, also known as the solarium due to its sunny disposition. The spirit was high, and we all felt like we could bring some joy to the clinic that day. I…
Erin Latimer Meadows |
Current ARHP President Afton L. Hassett, PsyD—a clinical psychologist and an associate research scientist in the Department of Anesthesiology at the University of Michigan—attended her first ACR/ARHP Annual Meeting in 1999. Dr. Hassett submitted an abstract to the meeting describing her dissertation research exploring the role of pain and depression in rheumatoid arthritis and fibromyalgia. It…
Gregory Taylor, MSW, RCSW |
Often, young adults (18–23 years old) with rheumatic illness demonstrate poor adherence to treatment regimens, lack advocacy skills and have inadequate knowledge about diagnosis and treatment.1 Patients presenting at a transition clinic are typically comfortable with having their parents continue to be centrally involved with their care, but this is a time in life when…
Sharad Lakhanpal, MBBS, MD |
May is National Arthritis Awareness Month. The ACR is committed to ensuring that arthritis and rheumatologic diseases are at the forefront of public awareness—and that better, safer treatments reach Americans in need. Fortunately, the federal government is also doing its part and has just released a major report on the national impact of arthritis. A…